Pharmacological reactivation of inactive X-linked Mecp2 in cerebral cortical neurons of living mice P Przanowski, U Wasko, Z Zheng, J Yu, R Sherman, LJ Zhu, ... Proceedings of the National Academy of Sciences 115 (31), 7991-7996, 2018 | 51 | 2018 |
Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy PM Jurek, K Zabłocki, U Waśko, MP Mazurek, J Otlewski, F Jeleń International Journal of Nanomedicine, 2941-2950, 2017 | 49 | 2017 |
Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer UN Wasko, J Jiang, TC Dalton, A Curiel-Garcia, AC Edwards, Y Wang, ... Nature, 1-3, 2024 | 30 | 2024 |
Tumor explants elucidate a Cascade of Paracrine SHH, WNT, and VEGF signals driving pancreatic Cancer Angiosuppression MC Hasselluhn, AR Decker-Farrell, L Vlahos, DH Thomas, ... Cancer discovery 14 (2), 348-361, 2024 | 7 | 2024 |
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma UN Wasko, J Jiang, A Curiel-Garcia, Y Wang, B Lee, M Orlen, ... bioRxiv, 2023 | 7 | 2023 |
Visualization of Xist Long Noncoding RNA with a Fluorescent CRISPR/Cas9 System U Waśko, Z Zheng, S Bhatnagar Epitranscriptomics: Methods and Protocols, 41-50, 2019 | 7 | 2019 |
Novel molecular players of X chromosome inactivation: new technologies and new insights P Przanowski, U Waśko, S Bhatnagar J Transl Genet Genom 2 (2), 2, 2018 | 5 | 2018 |
Developmental and MAPK-responsive transcription factors drive distinct malignant subtypes and genetic dependencies in pancreatic cancer P Laise, M Turunen, AC Garcia, L Tomassoni, HC Maurer, E Elyada, ... bioRxiv, 2020.10. 27.357269, 2020 | 3 | 2020 |
A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome P Przanowski, Z Zheng, U Wasko, S Bhatnagar JoVE (Journal of Visualized Experiments), e59449, 2019 | 2 | 2019 |
Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma UN Wasko, SA Sastra, CF Palermo, D Wildes, M Singh, KP Olive Cancer Research 83 (7_Supplement), 1725-1725, 2023 | 1 | 2023 |
Abstract B071: Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma UN Wasko, SA Sastra, CF Palermo, D Wildes, M Singh, KP Olive Cancer Research 82 (22_Supplement), B071-B071, 2022 | 1 | 2022 |
Abstract B014: Leveraging T cell anti-tumor immunity to enhance the efficacy of Ras inhibition in pancreatic cancer T Dalton, U Wasko, A Curiel-Garcia, S Sastra, C Palermo, M Hasselluhn, ... Cancer Immunology Research 12 (10_Supplement), B014-B014, 2024 | | 2024 |
Abstract C023: PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models BW Labadie, AZ Obradovic, SS Ana, M May, N Sender, IV Ross, ... Cancer Research 84 (17_Supplement_2), C023-C023, 2024 | | 2024 |
Adaptive heterogeneity enables the survival of residual malignant PDAC cells in response to RAS-GTP inhibition L Tomassoni, UN Wasko, AC Garcia, TC Dalton, P Laise, SA Sastra, ... Cancer Research 84 (6_Supplement), 3874-3874, 2024 | | 2024 |
RAS-GTP inhibition modulates Hedgehog signaling, suppressing myCAFs and promoting iCAFs in pancreatic ductal adenocarcinoma M Hasselluhn, L Tomassoni, U Wasko, A Curiel-Garcia, T Dalton, ... Cancer Research 84 (6_Supplement), 1578-1578, 2024 | | 2024 |
RNA-based precision medicine predicts sensitivity to selinexor in select pancreatic ductal adenocarcinoma patients A Curiel-Garcia, L Tomassoni, TC Dalton, AR Decker-Farrell, CF Palermo, ... Cancer Research 84 (6_Supplement), 934-934, 2024 | | 2024 |
Resistance to RAS-GTP inhibition in models of pancreatic ductal adenocarcinoma arises downstream of RAS effectors UN Wasko, J Jiang, TC Dalton, A Curiel-Garcia, AC Edwards, Y Wang, ... Cancer Research 84 (6_Supplement), 1927-1927, 2024 | | 2024 |
Abstract B101: Tumor-selective inhibition of active RAS in pancreatic ductal adenocarcinoma UN Wasko, J Jiang, L Tomassoni, Y Wang, B Lee, M Orlen, ... Cancer Research 84 (2_Supplement), B101-B101, 2024 | | 2024 |
Abstract C60: Combination of MEK and autophagy inhibition promotes tumor regression in the KPC mouse model of pancreatic cancer UN Wasko, SA Sastra, CF Palermo, KP Olive Cancer Research 79 (24_Supplement), C60-C60, 2019 | | 2019 |